Frederick Frank
Chairman of the Board, Director, Lehman Brothers
Mr. Frank is a Director of Lehman Brothers. Before joining Lehman Brothers as a Partner in October 1969, Mr. Frank was co-director of research, as well as Vice President and Director, of Smith, Barney & Co. Inc. He is a Chartered Financial Analyst, a member of The New York Society of Security Analysts and a past president of the Chemical Processing Industry Analysts. In addition to serving as the Chairman of the Board of Epix, Mr. Frank is a director of Business Engine, Diagnostic Products Corporation, Digital Arts & Sciences, Inc., eSoft, Inc., Landec Corporation, and Pharmaceutical Product Development, Inc. He is Chairman of the National Genetics Foundation, a director of the Salk Institute, a member of the Pharmaceutical Executive Magazine advisory board, a member of the Board of Governors of the National Center for Genome Resources and Chairman of the Board of The Irvington Institute for Immunological Research. Mr. Frank holds a B.A. from Yale University and an MBA from Stanford Business School.
Michael Gilman, Ph.D.
Dr. Gilman was most recently Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. Dr. Gilman was Executive Vice President and Chief Scientific Officer of ARIAD Pharmaceuticals from 1995 to 2000. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanism of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.
Michael G. Kauffman, M.D., Ph.D.
Chief Executive Officer, EPIX Pharmaceuticals
Dr. Kauffman received his M.D. and Ph.D. (molecular biology and biochemistry) at Johns Hopkins and his postdoctoral training at Harvard University. He is board certified in internal medicine, and comes with over 10 years of extensive experience in drug discovery and development. From September 2002 until August 2003, Dr. Kauffman served as President and Chief Executive Office of Epix Pharmaceuticals, Inc., the wholly-owned U.S. subsidiary of Epix Pharmaceuticals Ltd., an Israeli corporation that Epix acquired in august 2003. Dr. Kauffman joined Epix after being the Vice President, Medicine, and Proteasome Inhibitor (VELCADE™) Program Leader at Millennium Pharmaceuticals Inc. Prior to that, Dr. Kauffman held senior positions at Millennium Predictive Medicine, Inc., as cofounder and Vice President of Medicine, and at Biogen Corporation. He currently serves on the board of directors of Bioenvision, Inc., a publicly traded biopharmaceutical company, CombinatoRx, Inc., a publicly trades biopharmaceutical company.
Mark Leuchtenberger
President and Chief Executive Officer, Targanta Therapeutics Inc.
Mr. Leuchtenberger became President and Chief Executive Officer of Targanta Therapeutics, a privately held NDA stage antibiotics company, in 2006. Mr. Leuchtenberger joined Targanta from Therion Biologics Corporation, a privately held cancer vaccine company, where he served as President and Chief Executive Officer from 2002 to 2006. Under his leadership, Therion filed its first IND, progressed through Phase 3 trials, completed the buildup of its commercial manufacturing capabilities, and raised over $120 million in three rounds of private financings. Prior to joining Therion in 2002, Mr. Leuchtenberger spent 11 years at Biogen, Inc., where he led the development and launch of Avonex and ran North American and international commercial operations. Prior to Biogen, he was a consultant at Bain & Company specializing in healthcare. Mr. Leuchtenberger also serves on boards for the Massachusetts Biotechnology Council, Beth Israel Deaconess Medical Center and Wake Forest University.
Robert J. Perez
Senior Vice President, Commercial Operations, Cubist Pharmaceuticals
Mr. Perez has served at Senior Vice President, Commercial Operations for Cubist Pharmaceuticals since July 2004 and served as Cubist's Senior Vice President, Sales and Marketing from August 2003 to July 2004. Prior to joining Cubist, Mr. Perez served as Vice President of Biogen's Central Nervous System Business Unity since 2001 where he was responsible for leading the U.S. neurology franchise, including Biogen's product Avonex. From 1995 to 2001 he served as a Regional Director, Director of Sales, and Avonex Commercial Executive at Biogen. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals, ultimately serving as Regional Business Directors, responsible for strategic planning and profitability of the western regional business unit, managing both national accounts and regional sales managers. Mr. Perez received a B.S. from California State University, Los Angeles and an MBA from The Anderson School at UCLA.
Gregory D. Phelps
Chairman, President and Chief Executive Officer, RenaMed Biologics, Inc.
Mr. Phelps is the Chairman of the Board, President, and Chief Executive Officer of RenaMed Biologics, Inc., a biotechnology company developing therapeutic products. He has previously held positions of Chief Executive Officer of Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc. He has also served as Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation and Vice President of Baxter Travenol Laboratories, Inc. (now Baxter Healthcare).
Ian F. Smith, CPA, ACA
Senior Vice President and Chief Financial Officer, Vertex Pharmaceuticals Incorporated
Mr. Smith is Senior Vice President and CFO of Vertex Pharmaceuticals Inc., a publicly traded biotechnology company. Prior to joining Vertex, Mr. Smith was a Partner with Ernst & Young LLP, where he served as a Partner in the Life Science and Technology practice. Mr. Smith received a B.A. with honors in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.
